Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies
Considering the demonstrated safety of atezolizumab-bevacizumab in randomized-controlled trials, this meta-analysis offers valuable insights into reported occurrences of adverse events. Our study highlights significant heterogeneity among studies, underscoring the need to improve adverse event recording. Understanding the incidence and severity of treatment-related adverse events beyond clinical trials is essential for prompt intervention and may help in preventing treatment discontinuation and complications, potentially leading to better outcomes without significantly compromising quality of life due to adverse events.
Authors
- Jean‐Charles Nault (ORCID: https://orcid.org/0000-0002-4875-9353)
- Όλγα Γιουλεμέ (ORCID: https://orcid.org/0000-0003-0176-3598)
- D C Pallas (ORCID: https://orcid.org/0009-0009-6803-3769)
- G. Nkontchou (ORCID: https://orcid.org/0000-0003-4697-2086)
- Alix Demory
- Lorraine Blaise (ORCID: https://orcid.org/0000-0001-5344-1625)
- Sabrina Sidali (ORCID: https://orcid.org/0000-0003-3282-9254)
- Claudia Campani (ORCID: https://orcid.org/0000-0003-3842-782X)
- Pierre Nahon (ORCID: https://orcid.org/0000-0003-2489-0768)
- Nathalie Ganne‐Carrié (ORCID: https://orcid.org/0000-0002-7351-5027)
- Véronique Grando
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Aristotle University of Thessaloniki (GR)
- Sorbonne Université (FR)
- Université Sorbonne Paris Nord (FR)
- Centre de Recherche des Cordeliers (FR)
- La Ligue Contre le Cancer (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Avicenne (FR)
- University of Florence (IT)
Publication Details
- Journal
- JHEP Reports
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.jhepr.2024.101190
- Citations
- 9
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.33